KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Sales (2016 - 2025)

Historic Return on Sales for Xenon Pharmaceuticals (XENE) over the last 12 years, with Q3 2025 value amounting to 42.69%.

  • Xenon Pharmaceuticals' Return on Sales changed N/A to 42.69% in Q3 2025 from the same period last year, while for Sep 2025 it was 42.69%, marking a year-over-year change of. This contributed to the annual value of 13.29% for FY2022, which is 90200.0% down from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Return on Sales stood at 42.69% for Q3 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Sales peaked at 2.24% during Q1 2022, and registered a low of 1240.73% during Q2 2023.
  • For the 4-year period, Xenon Pharmaceuticals' Return on Sales averaged around 148.52%, with its median value being 13.29% (2022).
  • In the last 5 years, Xenon Pharmaceuticals' Return on Sales surged by 13700bps in 2022 and then tumbled by -11826000bps in 2023.
  • Xenon Pharmaceuticals' Return on Sales (Quarter) stood at 6.84% in 2021, then crashed by -94bps to 13.29% in 2022, then plummeted by -9233bps to 1240.73% in 2023, then skyrocketed by 97bps to 42.69% in 2025.
  • Its last three reported values are 42.69% in Q3 2025, 38.94% for Q2 2025, and 8.67% during Q1 2025.